A Wake-up Call for Blood Pressure Medication Users: Prazosin Recall and Nitrosamine Contamination
In a recent development, the Food and Drug Administration (FDA) has issued a recall for a generic blood pressure medication, prazosin, due to elevated levels of cancer-causing chemicals called nitrosamines. This recall, announced by Teva Pharmaceuticals on October 7, 2025, affects over half a million prazosin capsules and has raised concerns among healthcare professionals and patients alike.
But here's where it gets controversial... The recall highlights a potential gap in the safety of older generic drugs, especially those manufactured overseas. As a pharmacologist and pharmacist, I've studied nitrosamine contamination in popular medications, and the findings are eye-opening.
What are Nitrosamines and Why are They a Concern?
Nitrosamines are by-products of various chemical reactions, formed when nitrite and amine groups interact. While small and occasional exposures are generally considered safe, some studies suggest that prolonged exposure to high levels of certain nitrosamines can be carcinogenic. This has led to a major effort by the FDA to identify and define safe levels of nitrosamines in prescription and over-the-counter drugs.
The Valsartan Incident: A Precedent for Nitrosamine Contamination
In 2018, European regulators discovered nitrosamine contamination in a blood pressure drug called valsartan. This revelation prompted multiple manufacturers, including Teva Pharmaceuticals, to recall the drug. Since then, the FDA has published industry guidance to control nitrosamine impurities in human drugs, with updated versions in 2021 and 2024.
The Prazosin Recall: What You Need to Know
Teva Pharmaceuticals' prazosin is one of many generic versions, but it's the only one currently affected by the recall. Patients can check their prescription labels for the abbreviations MFG or MFR, which indicate the manufacturer. If it reads "MFG Teva" or "MFR Teva," it means Teva Pharmaceuticals supplied the medication. The first four numbers of the National Drug Code (NDC) on the label also reveal the manufacturer or distributor, with Teva products bearing the number 0093.
If Teva is the distributor, patients can cross-reference their prescription number with the lot numbers on the FDA website to see if their medication is part of the recall. In such cases, pharmacies may have other generic versions of prazosin that are not affected. The FDA has given the recall a Class II status, indicating that the medication could lead to temporary or reversible adverse health consequences.
Alternatives and Next Steps
Patients taking prazosin should not stop their medication without consulting their physician first. The risk of temporarily taking tablets with elevated nitrosamine levels may be less than the risk of suddenly stopping the medication. Physicians may also prescribe alternative treatments like clonidine or trazodone.
The Safety of Older Generics: A Global Perspective
A recent study has found that generics made in India pose a 54.3% higher risk of serious adverse events compared to those made in the United States. This risk increases with the longevity of the drug's generic availability. The study suggests that crowded generic drug markets lead to lower-priced, lower-quality products, especially from developing countries.
Teva Pharmaceuticals has manufacturing plants worldwide, including in India, but the company has not disclosed the origin of the recalled prazosin capsules and their ingredients.
The FDA rates generic drug quality, but these ratings do not provide information about the manufacturing plants, which could be at higher risk for quality issues. Patients rely on pharmacies to procure safe generic versions, but without reliable quality information, pharmacies may not always make the safest choices for American consumers.
This article aims to shed light on a critical issue in the pharmaceutical industry, prompting further discussion and action to ensure the safety of generic medications.
